ALAnnemarie Larkin

Annemarie Larkin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Annemarie Larkin has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • An insight into the molecular genetics of a uveal melanoma patient cohort

    by Susan Kennedy, Michael Rice, Sinead Toomey, Noel Horgan, Bryan T. Hennessey, Annemarie Larkin

    Background/aims Uveal melanoma (UM) is a highly aggressive malignancy and presents a clinically significant unmet need in cancer therapeutics. The aim of this study was to identify previously unreported mutations in UM among an Irish cohort of patients which may have potential clinical relevance. Methods DNA was extracted from 36 intraocular melanoma patient samples and 4 metastatic melanoma samples among the patient cohort by microdissection from formalin-fixed paraffin embedded tissue blocks and underwent genotyping to test for known single nucleotide polymorphisms in 42 cancer associated genes. These mutations were analysed using a custom-designed sequenom panel. Results Using high-throughput genotyping, mutually exclusive GNAQ and GNA11 mutations were detected in 31 of 34 UM patients together with a number of non-synonymous changes in established cancer driver genes, PHLPP2, MET, PIK3R1 and IDH-1, variants which have not been previously associated with UM. Conclusion Given the lack of knowledge regarding the clinical relevance of the variants identified in this UM cohort and their likely pathogenic nature in other cancers, further studies of the functional impact of these variant mutations are warranted to establish possible previously, undescribed roles in UM pathogenesis, which may provide additional targets for future therapies.


  • Open Access

    A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer

    by Dermot O'Sullivan, Paul Dowling, Helena Joyce, Edel McAuley, Andrew McCann, Michael Henry, Brianan McGovern, Paul Barham, Fergal C Kelleher, Jean Murphy, et al.

    Discovery and validation of new antibody tractable targets is critical for the development of new antibody therapeutics to address unmet needs in oncology. A highly invasive clonal variant of the MDA-MB-435S cell line was used to generate monoclonal antibodies (MAbs), which were screened for anti-invasive activity against aggressive cancer cells in vitro. The molecular target of selected inhibitory MAb 9E1 was identified using immunoprecipitation/liquid chromatography-tandem mass spectrometry. The potential anti-tumour effects of MAb 9E1 were investigated in vitro together with immunohistochemical analysis of the 9E1 target antigen in normal and cancer tissues. MAb 9E1 significantly decreases invasion in pancreatic, lung squamous and breast cancer cells and silencing of its target antigen, which was revealed as AnxA6, leads to markedly reduced invasive capacity of pancreatic and lung squamous cancer in vitro. IHC using MAb 9E1 revealed that AnxA6 exhibits a high prevalence of membrane immunoreactivity across aggressive tumour types with restricted expression observed in the majority of normal tissues. In pancreatic ductal adenocarcinoma, high AnxA6 IHC score correlated with the presence of tumour budding at the invasive front of tumours (P=0.082), the presence of perineural invasion (P= <0.0001) and showed a weak correlation with reduced survival (P=0.2242). This study highlights the use of phenotypic hybridoma screening as an effective strategy to select a novel function-blocking MAb, 9E1 with anti-cancer activity in vitro. Moreover, through characterisation of the 9E1 target antigen, AnxA6, our findings support further investigation of AnxA6 as a potential candidate target for antibody-mediated inhibition of pancreatic cancer.


  • 7B7: a novel antibody directed against the Ku70/Ku80 heterodimer blocks invasion in pancreatic and lung cancer cells

    by Dermot O’sullivan, Michael Henry, Helena Joyce, Naomi Walsh, Edel Mc Auley, Paul Dowling, Niall Swan, Michael Moriarty, Paul Barnham, Martin Clynes, et al.

    Development of more effective therapeutic strategies for cancers of high unmet need requires the continued discovery of disease-specific protein targets for therapeutic antibody targeting. In order to identify novel proteins associated with cancer cell invasion/metastasis, we present here an alternative to antibody targeting of cell surface proteins with an established role in invasion; our functional antibody screening approach involves the isolation and selection of MAbs that are primarily screened for their ability to inhibit tumour invasion. A clonal population of the Mia PaCa-2, a pancreatic ductal adenocarcinoma (PDAC) cell line, which displays a highly invasive phenotype, was used to generate MAbs with the objective of identifying membrane targets directly involved in cancer invasion. Selected MAb 7B7 can significantly reduce invasion in a dose-responsive manner in Mia PaCa-2 clone 3 and DLKP-M squamous lung carcinoma cells. Using immunoprecipitation and liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis, the target antigen of anti-invasive antibody, 7B7, was determined to be the heterodimeric Ku antigen, Ku70/80, a core protein composed of the Ku70 and Ku80 subunits which is involved in non-homologous end-joining (NHEJ) DNA repair. RNA interference-mediated knockdown of Ku70 and Ku80 resulted in a marked decrease in the invasive capacity of Mia PaCa-2 clone 3 and DLKP-M cells, indicating that Ku70/Ku80 is functionally involved in pancreatic and lung cancer invasion. Immunohistochemical analysis demonstrated Ku70/Ku80 immunoreactivity in 37 PDAC tumours, indicating that this heterodimer is highly expressed in this aggressive cancer type. This study demonstrates that a functional MAb screening approach coupled with immunoprecipitation/proteomic analyses can be successfully applied to identify functional anti-invasive MAbs and potential novel targets for therapeutic antibody targeting.


  • Open Access

    Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma

    by Naomi Walsh, Annemarie Larkin, Susan Kennedy, Lisa Connolly, Jo Ballot, Wei Ooi, Giuseppe Gullo, John Crown, Martin Clynes, Lorraine O'Driscoll

    Background: Renal cell carcinoma patients respond poorly to conventional chemotherapy, this unresponsiveness may be attributable to multidrug resistance (MDR). The mechanisms of MDR in renal cancer are not fully understood and the specific contribution of ABC transporter proteins which have been implicated in the chemoresistance of various cancers has not been fully defined in this disease.Methods: In this retrospective study the expression of two of these transporter efflux pumps, namely MDR-1 P-gp (ABCB1) and MRP-1 (ABCC1) were studied by immunohistochemistry in archival material from 95 renal cell carcinoma patients.Results: In the first study investigating MDR-1 P-gpandMRP-1 protein expression patterns in renal cell carcinoma patients, high levels of expression of both efflux pumps are observed with 100% of tumours studied showing MDR-1 P-gpandMRP-1 positivity.Conclusion: Although these findings do not prove a causal role, the high frequency of tumours expressing these efflux pumps suggests that they may be important contributors to the chemoresistance of this tumour type.


  • Open Access

    Investigation of MRP‐1 protein and MDR‐1 P‐glycoprotein expression in invasive breast cancer: A prognostic study

    by Annemarie Larkin, Lorraine O'Driscoll, Susan Kennedy, Rachel Purcell, Elizabeth Moran, John Crown, Michael Parkinson, Martin Clynes

    The efficacy of breast cancer treatment is limited by the development of resistance to various chemotherapeutic agents. We conducted a retrospective study of the expression of 2 drug resistance efflux pumps, MRP‐1 and MDR‐1 Pgp, in 177 invasive breast carcinomas. Immunohistochemical expression of these proteins was correlated with clinicopathologic characteristics as well as relapse‐free survival (RFS) and overall survival (OS) times. MDR‐1 Pgp was associated strongly with higher histologic grade (grade III). A highly significant association was shown between MDR‐1 Pgp and MRP‐1 expression (p < 0.01), 47.4% of patients expressing both proteins; MRP‐1 was expressed in approximately 61% of patients and MDR‐1, in approximately 66% of patients. No association was shown in the overall group between either MDR‐1 Pgp or MRP‐1 and any of the other clinicopathologic features. Kaplan‐Meier analysis revealed that in a subset of patients with either high‐grade (grade III) stage 1 (node‐negative) or stage 2 (node‐positive) tumours who were treated with surgery followed by adjuvant chemotherapy, MRP‐1 expression in p < 0.02) and OS (p < 0.02). Using multivariate analysis, MRP‐1 expression in p < 0.01) and OS (p < 0.01) in this patient group but not in other groups. In this subgroup, no significant correlation was observed between expression of MDR‐1 Pgp and MRP‐1. While the number of patients with high‐grade tumours treated with adjuvant chemotherapy was small and further confirmatory research is warranted, it appears that assessment of MRP‐1 expression at diagnosis may offer useful prognostic information in subgroups of patients with stage 1 or stage 2 high‐grade tumours who receive CMF‐based adjuvant chemotherapy. Given the known substrate specificities of MRP‐1, any mechanistic relationship between MRP‐1 expression and CMF resistance remains unclear. No association was shown between MDR‐1 Pgp expression and either RFS or OS time in any subgroup of patients.


    • 22 May 2004
      • Vol. 24, 457-64

    Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer.

    by Robert O'Connor, Mary Heenan, Lisa Connolly, Annemarie Larkin, Martin Clynes

    A number of cellular proteins, including P-glycoprotein (P-gp) and Multiple drug Resistance Protein (MRP-1), act as drug efflux pumps and are important in the resistance of many cancers to chemotherapy. We previously reported that a small number of NSAIDs could inhibit the activity of MRP-1. We chose sulindac as a candidate agent for further investigation as it has the most favourable efficacy and toxicity profile of the agents available for a potential specific MRP-1 inhibitor. NCI H460 cells expressed MRP-1 protein (by Western blot) and also the toxicity of doxorubicin (a substrate of MRP-1) could be potentiated in this line using non-toxic concentrations of the MRP-1 substrate/inhibitor sulindac. These cells were implanted in nude mice and the animals divided into various groups which were administered doxorubicin and/or sulindac. Sulindac was shown to significantly potentiate the tumour growth inhibitor activity of doxorubicin in this MRP-1-overexpressing human tumour xenograft model. Sulindac may be clinically useful as an inhibitor of the MRP-1 cancer resistance mechanism.


  • Open Access

    A new monoclonal antibody that specifically recognises the MDR3‐encoded gene product

    by Annemarie Larkin, Elizabeth Moran, Denis Alexander, Gerard Doherty, Lisa Connolly, Susan M. Kennedy, Martin Clynes